Abstract
The present review will deal only with the so-called “circulating insulin antagonists”, the other aspects of insulin resistance such as abnormal B-cell secretory products or insulin target tissue defects being covered in other chapters. Circulating insulin antagonists are immunological, hormonal or metabolic, they will be successively considered (see Fig. 1).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Palmer JP, Asplin CM, demons P, Lyen K, Tatpati O, Raghu P, Paquette TL. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983, 222, 1337–1339
Luyckx AS, Daubresse JC, Lefèbvre P. L’intérêt des insulines monocomposées dans le traitement du diabète. Med. Hyg. 1974, 32, 1283–1286
Bloom SR, Adrian TE, Mitchell SJ, Barnes AJ, Polak JM. Dirty insulin, a stimulant to autoimmunity. Gut 1976, 17, 817
Fineberg SE, Galloway JA, Fineberg NS, Rathbun MJ, Hufferd S. Immunoginecity of recombinant DNA human insulin. Diabetologia 1983, 25, 465– 469.
Schernthaner G., Borkenstein M, Schober E, Fink M. Immunogenicity of human monocomponent insulin in man: long-term follow-up of 77 newly treated type 1 (insulin-dependent) diabetic patients. Diabetologia 1983 25, 192
Luyckx AS, Daubresse JC, Jaminet C, Scheen A, Lefèbvre PJ. Immunogenicity of semisynthetic human insulin in man. Long-term comparison with porcine monocomponent insulin. Diab. Metab. (Paris) (submitted)
Vaughan NJA, Matthews JA, Kurz AB, Nabarro JDN. The bioavailability of circulating antibody-bound insulin following insulin withdrawal in type 1 (insulin-dependent) diabetes. Diabetologia 1983, 24, 355–358
Madsbad et al. Personal communication
Benson E.A., Ho P, Wang C, Wu PC, Fredlund PN. Insulin autoimmunity as a cause of hypoglycemia. Arch. Intern. Med. 1984, 144, 2351–2354
Flier JS, Kahn CR, Roth J, Bar RS. Antibodies that impair insulin receptor binding in an unusual diabetic syndrome with severe insulin resistance. Science 1975, 190, 63–65
Kasuga M, Karlsson FA, Kahn CR. Insulin stimulates the phosphorylation of the 95,000 dal ton subunit of its own receptor. Science 1982, 215, 185–187
Schade DS, Eaton RP, Alberti KGMM, Johnston DG. Diabetic coma. University of New Mexico Press, Albuquerque, N.M., U.S.A. 1981, 250 pages.
Luyckx AS, Lefebvre PJ. Les glucagonomes. Diab. Metab. 1981, 7, 289–300
Lefebvre PJ, Luyckx AS. Glucagon and diabetes: a reappraisal. Diabetologie 1979, 16, 347–354
Campbell PJ, BoTli GB, Cryer PE, Gerich JE. Nocturnal spikes in growth hormone secretion cause the dawn phenomenon. Diabetologia 1984, 27, 262
Schade DS, Eaton RP. Pathogenesis of diabetic ketoacidosis: a reappraisal. Diabetes Care 1979, 2, 296–306
Olefsky JM. Insulin antagonists and resistance. In Diabetes Mellitus. Theory and Practice. 3rd Ed. Medic. Examin. Publish. Co., New-York, U.S.A., 1983, 151–178
Randle PJ, Hales CN, Garland PB, Newsholme EA. The glucose fatty-acid cycle its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, i, 785–789
Golay A, Felber JP, Meyer HU, Curchod B, Maeder E, Jequier E. Study on lipid metabolism in obesity diabetes. Metabolism 1984, 33, 111–116
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Martinus Nijhoff Publishers, Dordrecht
About this chapter
Cite this chapter
Lefebvre, P.J., Luyckx, A.S. (1986). Insulin antagonism. In: Radder, J.K., Lemkes, H.H.P.J., Krans, H.M.J. (eds) Pathogenesis and Treatment of Diabetes Mellitus. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-4301-8_7
Download citation
DOI: https://doi.org/10.1007/978-94-009-4301-8_7
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-8411-6
Online ISBN: 978-94-009-4301-8
eBook Packages: Springer Book Archive